SNYRQ on OTC
Synergy CHC Corp.
American medicinal chemicals and botanical products company. Summary from the record
Price unavailable
Last updated Oct 19, 2026.
Overview
Compare with C21 Investments Inc., Leef Brands Inc. or CYANOTECH CORP, or pick any stock.
- TickerSNYRQ on OTC1
- IndustryMedicinal Chemicals & Botanical Products1
- HeadquartersWestbrook, Maine1
- Incorporated inNV2
- Business address865 Spring Street, Westbrook, Me 040922
- Filer categoryNon-accelerated filer, Smaller reporting company2
See how the biggest companies compare on our leaderboards
Website: Our FOCUSfactor website helps to educate and inform consumers on our line of products. The website also serves as a direct-to-consumer sales channel for most FOCUSfactor products.3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Retail brought in 67% of the revenue Synergy CHC Corp. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2024 | 2025 |
|---|---|---|
| Retail | $26.5M | $22.2M |
| Online | $8.4M | $8.1M |
| License Revenue | $2.9M |
Business segments
Nutraceuticals brought in 98% of the revenue Synergy CHC Corp. broke down this way in fiscal 2025.
Business segments by year
| Business segments | 2024 | 2025 |
|---|---|---|
| Nutraceuticals | $33.4M | $29.7M |
| Beverages | $1.4M | $631.3K |
| Consumer goods | $16.9K | $18.0K |
Regions
United States brought in 90% of the revenue Synergy CHC Corp. broke down this way in fiscal 2025.
Regions by year
| Regions | 2024 | 2025 |
|---|---|---|
| United States | $30.8M | $27.3M |
| Canada | $3.9M | $2.4M |
| M X | $3.6K | $623.7K |
| Other | $73.0K | $20.7K |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue33¢$10.1M
- Other costs66¢$20.2M
- Income tax0¢$117.5K
Out of $30.4M in revenue.4 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | $30.4M | $34.8M |
| Cost of sales | $10.1M | $11.2M |
| Gross Profit | $20.3M | $23.6M |
| Selling and marketing | $13.1M | $13.0M |
| General and administrative | $8.8M | $4.7M |
| Reserve for bad debts | $6.7M | |
| Depreciation and amortization | $133.3K | $133.3K |
| Total operating expenses | $28.8M | $17.8M |
| (Loss) Income from operations | -$8.5M | $5.8M |
| Other income | -$510.5K | |
| Interest income | -$15.1K | -$1.5K |
| Interest expense | $5.9M | $4.1M |
| Gain on settlement of notes payable | -$2.2M | |
| Remeasurement loss (gain) on translation of foreign subsidiary | $14.8K | -$19.0K |
| Total other expenses | $3.8M | $3.6M |
| Net (loss) income before income taxes | -$12.2M | $2.2M |
| Income tax expense | $117.5K | $102.1K |
| Net (loss) income | -$12.3M | $2.1M |
| Net (loss) income per share basic (in Dollars per share) | -$1.27 | $0.28 |
| Net (loss) income per share - diluted (in Dollars per share) | -$1.27 | $0.28 |
| Basic (in Shares) | 9.7M shares | 7.6M shares |
| Diluted (in Shares) | 9.7M shares | 7.6M shares |
| Foreign currency translation adjustment | -$106.5K | $54.7K |
| Comprehensive (loss) income | -$12.4M | $2.2M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $2.6M | $687.9K | |
| Restricted cash | $100.0K | $100.0K | |
| Accounts receivable, net | $3.2M | $5.3M | |
| Other receivables, net | $2.0M | ||
| Prepaid expenses (including related party amount of $110,803 and $312,966, respectively) | $351.0K | $1.9M | |
| Inventory, net | $3.7M | $1.7M | |
| Total Current Assets | $10.0M | $16.1M | |
| Intangible assets, net | $150.0K | $283.3K | |
| Total Assets | $10.2M | $16.3M | |
| Accounts payable and accrued liabilities (including payable to shareholder of $196,934 and $88,644, respectively) | $6.4M | $5.2M | |
| Income taxes payable | $88.1K | $243.0K | |
| Contract liabilities | $1.5K | $24.3K | $14.2K |
| Short term loans payable, net of debt discount, related party | $100.0K | ||
| Short term loans payable, net of debt discount | $7.7M | ||
| Current portion of notes payable, net of debt discount | $1.7M | ||
| Current portion of long-term notes payable, net of debt discount and debt issuance cost, shareholder | $4.0M | ||
| Total Current Liabilities | $8.2M | $17.2M | |
| Notes payable, net of debt discount, shareholder | $8.3M | ||
| Notes payable, net of debt discount | $25.1M | $7.5M | |
| Total long-term liabilities | $25.1M | $15.8M | |
| Total Liabilities | $33.3M | $33.0M | |
| Common stock, $0.00001 par value; 300,000,000 shares authorized; 11,483,926 and 8,721,818, shares issued, respectively; 11,303,853 and 8,541,745 outstanding, respectively | $114 | $87 | |
| Additional paid in capital | $33.6M | $27.6M | |
| Accumulated other comprehensive loss | -$154.3K | -$47.8K | |
| Accumulated deficit | -$56.4M | -$44.1M | |
| Less: Treasury stock (180,073 shares) at cost | -$127.5K | -$127.5K | |
| Total stockholders deficit | -$23.1M | -$16.6M | -$27.3M |
| Total Liabilities and Stockholders Deficit | $10.2M | $16.3M | |
| Payable to shareholder | $196.9K | $88.6K | |
| Common stock par value (in Dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in Shares) | 300.0M shares | 300.0M shares | |
| Common stock, shares issued (in Shares) | 11.5M shares | 8.7M shares | |
| Common stock, shares outstanding (in Shares) | 11.3M shares | 8.5M shares | |
| Treasury stock cost (in Shares) | 180.1K shares | 180.1K shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $2.6M | $687.9K | |
| Restricted cash | $100.0K | $100.0K | |
| Accounts receivable, net | $3.2M | $5.3M | |
| Other receivables, net | $2.0M | ||
| Prepaid expenses (including related party amount of $110,803 and $312,966, respectively) | $351.0K | $1.9M | |
| Inventory, net | $3.7M | $1.7M | |
| Total Current Assets | $10.0M | $16.1M | |
| Intangible assets, net | $150.0K | $283.3K | |
| Total Assets | $10.2M | $16.3M | |
| Accounts payable and accrued liabilities (including payable to shareholder of $196,934 and $88,644, respectively) | $6.4M | $5.2M | |
| Income taxes payable | $88.1K | $243.0K | |
| Contract liabilities | $1.5K | $24.3K | $14.2K |
| Short term loans payable, net of debt discount, related party | $100.0K | ||
| Short term loans payable, net of debt discount | $7.7M | ||
| Current portion of notes payable, net of debt discount | $1.7M | ||
| Current portion of long-term notes payable, net of debt discount and debt issuance cost, shareholder | $4.0M | ||
| Total Current Liabilities | $8.2M | $17.2M | |
| Notes payable, net of debt discount, shareholder | $8.3M | ||
| Notes payable, net of debt discount | $25.1M | $7.5M | |
| Total long-term liabilities | $25.1M | $15.8M | |
| Total Liabilities | $33.3M | $33.0M | |
| Common stock, $0.00001 par value; 300,000,000 shares authorized; 11,483,926 and 8,721,818, shares issued, respectively; 11,303,853 and 8,541,745 outstanding, respectively | $114 | $87 | |
| Additional paid in capital | $33.6M | $27.6M | |
| Accumulated other comprehensive loss | -$154.3K | -$47.8K | |
| Accumulated deficit | -$56.4M | -$44.1M | |
| Less: Treasury stock (180,073 shares) at cost | -$127.5K | -$127.5K | |
| Total stockholders deficit | -$23.1M | -$16.6M | -$27.3M |
| Total Liabilities and Stockholders Deficit | $10.2M | $16.3M | |
| Payable to shareholder | $196.9K | $88.6K | |
| Common stock par value (in Dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in Shares) | 300.0M shares | 300.0M shares | |
| Common stock, shares issued (in Shares) | 11.5M shares | 8.7M shares | |
| Common stock, shares outstanding (in Shares) | 11.3M shares | 8.5M shares | |
| Treasury stock cost (in Shares) | 180.1K shares | 180.1K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net (loss) income | -$12.3M | $2.1M |
| Amortization of debt discount and debt issuance cost | $1.6M | $56.8K |
| Depreciation and amortization | $133.3K | $133.3K |
| Stock based compensation | $136.2K | |
| Stock issued for modification of notes payable | $847.1K | |
| Stock issued for services | $127.2K | |
| Foreign currency transaction (gain) loss | $5.5K | $54.3K |
| Remeasurement gain on translation of foreign subsidiary | $14.8K | -$19.0K |
| Non cash implied interest | $4.8K | |
| Bad debts | $2.3M | |
| Bad debt, related party | $4.4M | |
| Gain on settlement of debt | -$2.2M | |
| Write-off of inventory | $894.3K | $125.4K |
| Stock issued for loan financing | $97.9K | |
| Income from employee retention credits | -$252.4K | |
| Income from insurance on stolen goods | -$258.1K | |
| Accounts receivable | $1.5M | -$3.2M |
| Other receivables | $345.4K | -$1.5M |
| Loan receivable, related party | $84.9K | |
| Inventory | -$2.9M | $1.9M |
| Prepaid expenses | $1.3M | -$1.3M |
| Prepaid expense, related party | $202.2K | -$145.1K |
| Income taxes payable | -$84.3K | $57.3K |
| Contract liabilities | -$22.7K | $10.1K |
| Accounts payable and accrued liabilities | $622.1K | -$2.9M |
| Accounts payable, related party | $489.1K | $61.8K |
| Net cash used in operating activities | -$2.6M | -$4.8M |
| Proceeds from issuance of common stock at IPO | $8.4M | |
| Proceeds from issuing common stock | $3.7M | |
| Advances from related party | $235.0K | $3.5M |
| Repayments of advances to related party | -$135.0K | -$3.2M |
| Repayment of notes payable, shareholder | -$10.0M | -$84.5K |
| Proceeds from notes payable | $21.0M | $1.4M |
| Payment of loan financing fees | -$2.0M | |
| Repayment of notes payable | -$8.1M | -$5.2M |
| Net cash provided by financing activities | $4.7M | $4.8M |
| Effect of exchange rate on cash, cash equivalents and restricted cash | -$135.2K | $54.7K |
| Net increase in cash, cash equivalents and restricted cash | $1.9M | $55.4K |
| Interest | $3.0M | $3.9M |
| Income taxes | $147.4K | |
| Accounts payable converted to loan payable upon settlement | $3.8M | |
| Reduction of short term related party note payable by reduction of prepaid balance | $328.0K | |
| Issuance of common stock for loan financing | $220.9K | |
| Issuance of pre-funded warrants for settlement of shareholder notes payable | $900.0K | |
| Exercise of pre-funded warrants | $4 | |
| Loan fees payable to lender | $375.0K |
No quarter-by-quarter statement was filed.
Leadership
Who has led Synergy CHC Corp., and when. Pick a name to see everywhere that person has worked.
Chief financial officer
- PresidentAlfred Baumeler Oct 22, 2024 to now10
- PresidentPatrick S. McCullough Nov 6, 2017 to Nov 6, 201711
- Chief financial officerJaime Fickett Sep 22, 2025 to now12
- Chief financial officerStacy B. McLaughlin Oct 22, 2024 to Oct 22, 202413
- Chief financial officerJeffrey Kadanoff Nov 1, 2017 to Nov 1, 201714
Board members and other officers (8)
- Senior VP Finance & OperationsJaime Fickett Oct 22, 2024 to Oct 22, 202415
- Board memberTeresa Brigid Thompson Oct 2, 2025 to now16
- Board memberAlfred Baumeler Oct 22, 2024 to now10
- Board memberNitin Kaushal Oct 22, 2024 to now17
- Board memberScott Woodburn Oct 22, 2024 to Oct 22, 202418
- Board memberGale K. Bensussen Oct 20, 2017 to Oct 20, 201719
- Board memberStephen J. Fryer Feb 9, 2015 to Dec 16, 201520
- Board memberJames Paul Sorelle Feb 10, 2015 to Oct 22, 202421
Former names
Filings
123 filings to the SEC since October 2021: 2 annual reports, 5 quarterly reports, 25 major events, 25 insider forms, 4 large holders, 62 other. The latest 20:
- Sep 16, 20268-K CURRENT REPORT EDGAR
- Sep 8, 20268-K CURRENT REPORT EDGAR
- Aug 26, 20268-K CURRENT REPORT EDGAR
- Aug 21, 20268-K CURRENT REPORT EDGAR
- Aug 11, 20268-K CURRENT REPORT EDGAR
- Jul 29, 20268-K CURRENT REPORT EDGAR
- Jul 1, 20264 PRIMARY DOCUMENT EDGAR
- Jul 1, 20264 PRIMARY DOCUMENT EDGAR
- Jul 1, 20264 PRIMARY DOCUMENT EDGAR
- Jun 29, 20268-K CURRENT REPORT EDGAR
- May 22, 2026EFFECT EDGAR
- May 21, 2026CORRESP EDGAR
- May 21, 2026UPLOAD EDGAR
- May 18, 20268-K CURRENT REPORT EDGAR
- May 15, 2026S-1 REGISTRATION STATEMENT EDGAR
- May 14, 20268-K CURRENT REPORT EDGAR
- May 14, 202610-Q QUARTERLY REPORT EDGAR
- May 11, 20268-K CURRENT REPORT EDGAR
- Apr 30, 2026ARS ANNUAL REPORT EDGAR
- Apr 30, 2026DEFA14A DEFINITIVE ADDITIONAL MATERIALS EDGAR
The 123 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
123 open-market trades by officers, directors and large owners since October 2021: 123 buys and 0 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 30, 2025 | Ross JackCEO and Chairman | Buy | 100 | $3.69 | $369 | Form 4 |
| Jul 29, 2025 | Ross JackCEO and Chairman | Buy | 250 | $3.66 | $915 | Form 4 |
| Jul 25, 2025 | Ross JackCEO and Chairman | Buy | 350 | $3.90 | $1.4K | Form 4 |
| Jul 24, 2025 | Ross JackCEO and Chairman | Buy | 300 | $3.83 | $1.1K | Form 4 |
| Jul 22, 2025 | Ross JackCEO and Chairman | Buy | 300 | $3.54 | $1.1K | Form 4 |
| Jul 11, 2025 | Ross JackCEO and Chairman | Buy | 750 | $3.20 | $2.4K | Form 4 |
| Jul 10, 2025 | Ross JackCEO and Chairman | Buy | 1,400 | $3.19 | $4.5K | Form 4 |
| Jul 9, 2025 | Ross JackCEO and Chairman | Buy | 400 | $3.15 | $1.3K | Form 4 |
| Jul 8, 2025 | Ross JackCEO and Chairman | Buy | 800 | $3.36 | $2.7K | Form 4 |
| Jul 7, 2025 | Ross JackCEO and Chairman | Buy | 700 | $3.26 | $2.3K | Form 4 |
| Jul 3, 2025 | Ross JackCEO and Chairman | Buy | 1,750 | $3.22 | $5.6K | Form 4 |
| Jul 2, 2025 | Ross JackCEO and Chairman | Buy | 3,750 | $3.23 | $12.1K | Form 4 |
| Jul 1, 2025 | Ross JackCEO and Chairman | Buy | 250 | $3.05 | $762 | Form 4 |
| Jun 30, 2025 | Ross JackCEO and Chairman | Buy | 2,600 | $2.69 | $7.0K | Form 4 |
| Jun 27, 2025 | Ross JackCEO and Chairman | Buy | 100 | $2.60 | $260 | Form 4 |
| Jun 26, 2025 | Ross JackCEO and Chairman | Buy | 650 | $2.55 | $1.7K | Form 4 |
| Jun 24, 2025 | Ross JackCEO and Chairman | Buy | 600 | $2.63 | $1.6K | Form 4 |
| Jun 23, 2025 | Ross JackCEO and Chairman | Buy | 400 | $2.61 | $1.0K | Form 4 |
| Jun 20, 2025 | Ross JackCEO and Chairman | Buy | 10,300 | $2.60 | $26.8K | Form 4 |
| Jun 18, 2025 | Ross JackCEO and Chairman | Buy | 600 | $2.23 | $1.3K | Form 4 |
All 123 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Knight Therapeutics Inc.SCHEDULE 13G/A, 2 filings Mar 20, 2025 to Jun 13, 202522
- Jack RossSC 13D, 1 filing Oct 31, 202423
- SANDERS MORRIS HARRIS LLCSC 13G, 1 filing Oct 25, 202424
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Jane Street Group, LLC | 181,648 | $36.1K | 0.0% | New |
| ACT Advisors, LLC. | 151,840 | $30.1K | 0.0% | New |
| XTX Topco Ltd | 61,270 | $12.2K | 0.0% | New |
| Vanguard Capital Management LLC | 38,909 | $7.7K | 0.0% | −50,861 |
| Geode Capital Management, LLC | 32,775 | $6.5K | 0.0% | +11,377 |
| Vanguard Fiduciary Trust Co | 16,008 | $3.2K | 0.0% | −7,141 |
| StoneX Group Inc. | 15,109 | $3.0K | 0.0% | New |
| Ewa, LLC | 13,727 | $2.7K | 0.0% | New |
| Citadel Advisors LLC | 10,902 | $2.2K | 0.0% | New |
| Williams & Novak, LLC | 10,020 | $2.0K | 0.0% | −1,925 |
| Tower Research Capital LLC (TRC) | 3,714 | $737 | 0.0% | +822 |
| Barclays PLC | 884 | $175 | 0.0% | New |
| Hrt Financial LP | 34,035 | $6 | 0.0% | New |
| Virtu Financial LLC | 18,539 | $4 | 0.0% | New |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10SEC EDGARAlfred Baumeler, President
- 11SEC EDGARPatrick S. McCullough, President
- 12
- 13
- 14
- 15
- 16SEC EDGARTeresa Brigid Thompson, Board member
- 17SEC EDGARNitin Kaushal, Board member
- 18SEC EDGARScott Woodburn, Board member
- 19SEC EDGARGale K. Bensussen, Board member
- 20SEC EDGARStephen J. Fryer, Board member
- 21SEC EDGARJames Paul Sorelle, Board member
- 22
- 23
- 24